上海医药
上海醫藥
상해의약
Shanghai Medical & Pharmaceutical Journal
2015年
21期
6-8,35
,共4页
肝细胞癌%索拉非尼%分子靶向治疗
肝細胞癌%索拉非尼%分子靶嚮治療
간세포암%색랍비니%분자파향치료
hepatocellular carcinoma%sorafenib%molecular targeted therapy
肝细胞癌的发病率和死亡率仍居高不下，手术是其治疗的首选方法，但手术切除率低，肿瘤易复发、转移。多靶点激酶抑制剂索拉非尼是第一个被批准用于治疗肝细胞癌的分子靶向药物。本文就索拉非尼在肝细胞癌治疗中的临床作用、与其他治疗手段的联合应用和毒副反应的防治等作一综述。
肝細胞癌的髮病率和死亡率仍居高不下，手術是其治療的首選方法，但手術切除率低，腫瘤易複髮、轉移。多靶點激酶抑製劑索拉非尼是第一箇被批準用于治療肝細胞癌的分子靶嚮藥物。本文就索拉非尼在肝細胞癌治療中的臨床作用、與其他治療手段的聯閤應用和毒副反應的防治等作一綜述。
간세포암적발병솔화사망솔잉거고불하，수술시기치료적수선방법，단수술절제솔저，종류역복발、전이。다파점격매억제제색랍비니시제일개피비준용우치료간세포암적분자파향약물。본문취색랍비니재간세포암치료중적림상작용、여기타치료수단적연합응용화독부반응적방치등작일종술。
The morbidity and mortality of hepatocellular carcinoma remain high. Radical resection rate is low although operation is still the first choice for the treatment of hepatocellular carcinoma. Post-operation metastasis and recurrence are challenging. Sorafenib as a small molecule multi-targeted kinase inhibitor is widely used in the treatment of hepatocellular carcinoma. The efifcacy of sorafenib treatment, its combined use with other therapy and the management of its adverse events are reviewed in this article.
